{"id":1836,"date":"2023-12-13T13:00:06","date_gmt":"2023-12-13T12:00:06","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1836"},"modified":"2023-12-13T12:05:46","modified_gmt":"2023-12-13T11:05:46","slug":"dextech-medical-informs-about-the-myeloma-study-the-first-patient-is-treated","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/dextech-medical-informs-about-the-myeloma-study-the-first-patient-is-treated\/","title":{"rendered":"DexTech Medical informs about the myeloma study, the first patient is treated"},"content":{"rendered":"
\n
\n
\n

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. The study includes a total of 20 patients and will initially be conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and So\u0308dersjukhuset in Stockholm. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology\/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. Biochemical markers are continuously analyzed, and the first assay results are expected in Q1-24.
\nThe study is expected to be completed in Q4, 2024.<\/p>\n

The work to seek partnerships regarding continued clinical development of OsteoDex – mCRPC towards phase 3 – is ongoing. The Company’s synthesis patent application, filed with the European Patent Office (EPO.Org) in October -23, is of great importance for the Company’s opportunities for partnership as well as positive results from the Company’s MM study. The conditions for the patent application to be granted are good, resulting in market exclusivity until 2044. Without prejudging the results from the MM study, Osteodex’s positive effect on bone-degrading bone cells and the absence of serious side effects are well documented and will probably be confirmed in the MM study as well.<\/p>\n

For more information about DexTech, please contact:<\/strong><\/p>\n

Go\u0308sta Lundgren \u2013 CFO
\nDexTech Medical AB
\nPhone: +46 (0) 707104788
\nE-mail: gosta.lundgren@dextechmedical.com<\/p>\n

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 13, 2023.<\/em><\/p>\n

231213 – PR – Dextech informs about the myeloma study, the first patient is treated<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1836","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"\nDexTech Medical informs about the myeloma study, the first patient is treated | DexTech<\/title>\n<meta name=\"description\" content=\"The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/?p=1832\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DexTech Medical informs about the myeloma study, the first patient is treated | DexTech\" \/>\n<meta property=\"og:description\" content=\"The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/?p=1832\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-13T12:00:06+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1832\",\"url\":\"https:\/\/dextechmedical.com\/?p=1832\",\"name\":\"DexTech Medical informs about the myeloma study, the first patient is treated | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2023-12-13T12:00:06+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/?p=1832#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/?p=1832\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1832#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DexTech Medical informs about the myeloma study, the first patient is treated\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DexTech Medical informs about the myeloma study, the first patient is treated | DexTech","description":"The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/?p=1832","og_locale":"en_US","og_type":"article","og_title":"DexTech Medical informs about the myeloma study, the first patient is treated | DexTech","og_description":"The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at","og_url":"https:\/\/dextechmedical.com\/?p=1832","og_site_name":"DexTech","article_published_time":"2023-12-13T12:00:06+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/?p=1832","url":"https:\/\/dextechmedical.com\/?p=1832","name":"DexTech Medical informs about the myeloma study, the first patient is treated | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2023-12-13T12:00:06+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/?p=1832#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/?p=1832"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/?p=1832#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"DexTech Medical informs about the myeloma study, the first patient is treated"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1836"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1836\/revisions"}],"predecessor-version":[{"id":1839,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1836\/revisions\/1839"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}